AGIO 88.40 Agios Pharmaceuticals Inc $AGIO Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 10:11 AM

AGIO 88.40 Agios Pharmaceuticals Inc $AGIO Hit a 52 week high of 87.99 Closing the day 09:45 at 88.40 +1.53 +1.76% With a day low of 87.00 and a total volume of 61,098.

AGIO Recent Posts: http://investorshangout.com/Agios-Pharmaceuti...GIO-90049/

AGIO Agios Pharmaceuticals Inc Recent Headline News

Jim Cramer Says to Buy Six Flags, Avoid SeaWorld Entertainment
at The Street - Wed Nov 12, 1:20PM CST
TheStreet's Jim Cramer says investors shouldn't be tricked by SeaWorld's attractive dividend yield. Instead, stick with Six Flags Entertainment.
SEAS: 16.81 (-0.04), SIX: 40.83 (-0.04), AGIO: 87.20 (+0.33)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ICUI: 84.08 (-0.65), OREX: 5.97 (+0.13), PCMI: 8.80 (-0.10), CYAN: 6.20 (+0.22), ACHN: 14.27 (-0.58), TGTX: 14.36 (+0.33), AGIO: 87.20 (+0.33), LIOX: 5.40 (-0.03), SAJA: 5.90 (-0.35), PLNR: 7.16 (+0.01)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 175.14 (+1.46), SLXP: 96.55 (+1.00), ICPT: 160.25 (-2.71), IBB: 297.25 (+0.76), AGIO: 87.20 (+0.33)

Agios Pharmaceuticals' (AGIO) CEO David Schenkein on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:31AM CST

AGIO: 87.20 (+0.33)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:14AM CST

BEBE: 2.47 (unch), ANET: 78.40 (+1.16), TKMR: 16.21 (+0.11), ORBC: 6.53 (-0.04), MDRX: 12.22 (+0.27), RMTI: 11.15 (-0.09), CTIC: 2.17 (-0.01), SHLD: 39.50 (+1.74), UBNT: 28.85 (-0.15), RIG: 27.03 (-0.05), KGC: 2.43 (-0.03), APT: 2.97 (-0.03), ANF: 29.68 (+0.33), MITK: 3.57 (-0.09), ZNGA: 2.91 (+0.10), CNET: 2.18 (+0.03), KING: 15.00 (+0.97), NETE: 1.39 (-0.01), SLXP: 96.55 (+1.00), RPRX: 10.11 (+0.68), NADL: 4.76 (-0.18), PGNX: 6.81 (+0.20), AVNR: 13.34 (+0.16), FSLR: 48.32 (-1.27), DVA: 77.13 (+0.41), NDLS: 24.09 (-0.05), ICPT: 160.25 (-2.71), AGIO: 87.20 (+0.33), PLNR: 7.16 (+0.01)

Agios Pharmaceuticals EPS of $0.10
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:11AM CST

AGIO: 87.20 (+0.33)

Agios Pharmaceuticals posts 3Q profit
Automated Insights - Fri Nov 07, 6:09AM CST
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Friday reported earnings of $3.7 million, or 10 cents per share, in its third quarter.
AGIO: 87.20 (+0.33)

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Fri Nov 07, 6:00AM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported business highlights and financial results for the third quarter ended September 30, 2014.
AGIO: 87.20 (+0.33)

Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:30PM CST

BAM: 50.01 (+0.15), ERF: 15.07 (-0.33), LXP: 11.08 (+0.09), PGEM: 13.00 (-0.02), CCOI: 35.76 (+0.84), TTI: 8.36 (-0.18), SJI: 57.94 (-0.12), NXST: 46.15 (+0.62), VSAT: 63.97 (-0.04), MT: 12.11 (+0.08), LXU: 33.28 (-0.08), HUM: 138.04 (+0.79), PGNX: 6.81 (+0.20), MHR: 4.74 (-0.07), CTB: 32.66 (+0.06), IDRA: 2.53 (-0.03), ISIS: 52.74 (+1.66), BPL: 80.20 (+0.74), SSP: 19.24 (+0.27), AGIO: 87.20 (+0.33), EBIX: 16.56 (unch)

Will Agios (AGIO) Disappoint in the Q3 Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:10PM CST
Agios (AGIO), which is scheduled to report third-quarter results on Nov 7, had delivered a negative earnings surprise of 14.89% in the last quarter.
MNK: 86.07 (-6.92), RNA: 11.73 (-0.02), AGIO: 87.20 (+0.33), CELG: 108.53 (+0.28)

Agios Pharmaceuticals to Present Clinical and Preclinical Data at the 2014 American Society of Hematology Annual Meeting
GlobeNewswire - Thu Nov 06, 8:46AM CST
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation
AGIO: 87.20 (+0.33)

Critical Alerts For LinkedIn, Imperva Inc, Norfolk Southern, Halliburton and Agios Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 03, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LNKD, IMPV, NSC, HAL and AGIO.
NSC: 116.04 (-0.62), LNKD: 233.65 (+2.52), HAL: 52.40 (-0.83), AGIO: 87.20 (+0.33), IMPV: 45.11 (+0.46)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 105.20 (-1.70), CLVS: 59.02 (+0.58), ARWR: 6.53 (unch), ACHN: 14.28 (-0.57), MRK: 59.89 (+0.58), RTRX: 11.87 (+0.31), RGLS: 18.00 (-1.62), EPZM: 23.73 (-0.15), AGIO: 87.20 (+0.33), RMTI: 11.15 (-0.09), ARNA: 4.84 (+0.14), KERX: 15.86 (+0.27)

Cramer's Lightning Round - Isis Pharmaceuticals Has The Best Pipeline (10/28/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Oct 29, 5:59AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday October 2 8. Bullish Calls: Isis Pharmaceuticals (NASDAQ: ISIS ): "Isis got slammed, and (the selloff) was overdone. It has the best pipeline...
GS: 189.92 (-0.26), RICE: 25.80 (-0.41), ISIS: 52.74 (+1.66), CYBR: 39.20 (+5.50), GNC: 43.75 (-0.47), HAL: 52.40 (-0.83), AGIO: 87.20 (+0.33), FTNT: 27.30 (+0.14)

'Mad Money' Lightning Round: I'm Sticking With Isis Pharmaceuticals
at The Street - Wed Oct 29, 5:00AM CDT
Cramer says Halliburton is a buy, buy, buy and GNC needs to merge with Vitamin Shoppe.
VSI: 48.19 (+0.03), RICE: 25.80 (-0.41), GS: 189.92 (-0.26), FEYE: 34.04 (+0.89), ISIS: 52.74 (+1.66), CYBR: 39.20 (+5.50), GNC: 43.75 (-0.47), HAL: 52.40 (-0.83), EOG: 96.73 (-0.83), AGIO: 87.20 (+0.33), FTNT: 27.30 (+0.14)

Jim Cramer's 'Mad Money' Recap: Winners in the Expectations Game
at The Street - Tue Oct 28, 7:26PM CDT
It's expectations, not the earnings, that determine the direction of a company's stock price, and several companies proved that today, Cramer says.
KSS: 56.05 (-1.86), FEYE: 34.04 (+0.89), CYBR: 39.20 (+5.50), FB: 74.89 (+0.17), GNC: 43.75 (-0.47), HAL: 52.40 (-0.83), AGCO: 44.72 (-0.13), BWLD: 163.37 (+0.37), MAS: 23.22 (+0.03), YHOO: 50.99 (+0.39), WHR: 175.74 (+0.53), VSI: 48.19 (+0.03), SAVE: 78.50 (+0.14), RICE: 25.80 (-0.41), GS: 189.92 (-0.26), PH: 128.55 (-0.02), ISIS: 52.74 (+1.66), CMI: 146.06 (-0.43), EOG: 96.73 (-0.83), AGIO: 87.20 (+0.33), TWTR: 43.18 (+0.64), FTNT: 27.30 (+0.14), BABA: 119.73 (+1.53)

Can Celgene Corporation Stock Motor to $150 Following Earnings?
Sean Williams, The Motley Fool - Motley Fool - Tue Oct 28, 7:03AM CDT
Just as the proverbial American worker stamps their time card on a daily basis and does their job, biotech giant Celgene continues to deliver for shareholders without fail. Last Thursday, Celgene dazzled investors yet again by reporting better...
OMED: 21.46 (+0.16), AGIO: 87.20 (+0.33), CELG: 108.53 (+0.28)

Forget MannKind Corporation: 3 Better Stocks
Motley Fool Staff - Motley Fool - Mon Oct 27, 8:13AM CDT
Source: MannKind. A doubling of Americans diagnosed with diabetes over the coming decade may support demand for MannKind 's inhalable insulin Afrezza, but that doesn't necessarily mean that MannKind is biotech's best idea. We asked three of...
DXCM: 53.53 (-0.48), NVAX: 5.30 (+0.06), AGIO: 87.20 (+0.33), SNY: 46.77 (+0.21), MNKD: 6.19 (+0.11), CELG: 108.53 (+0.28)

Agios Pharmaceuticals to Webcast Conference Call of Third Quarter 2014 Financial Results on November 7, 2014
GlobeNewswire - Mon Oct 27, 7:41AM CDT
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that it will host a conference call and live webcast on Friday, November 7, 2014, at 8:00 a.m. EST to report its third quarter 2014 financial results and discuss recent business activities.
AGIO: 87.20 (+0.33)

Agios Pharmaceuticals Inc. (AGIO) Stock Research Links

AGIO Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alliant's Ritchie Earns Titan 100 Honor—A Leader's Impact

Ritchie's Recognition: An Ongoing Leadership Journey When leadership is genuine, it resonates through the ranks all the way to the community. That's exactly what Meredith Ritchie, EVP at Alliant Credit Union, has been doing—and it shows as she nabs the Chicago Titan 100 accolade yet again in 2027. These folks at Titan 100 don’t hand out participation trophies;...

Newsday Unveils Essential Guide to NY Colleges

Launching a Comprehensive College Resource Ah, the college decision stress. Back in the day it was simpler, just pick a campus that looked good on paper and hope for the best. But now? Kids and their families have got a minefield of information to navigate. Time to make room at the table for Newsday's latest attempt to unravel the college chaos with their Essential Guide...

Natura's 3Q26 Performance: Navigating Bottlenecks and Potential

Unexpected Performance Amidst Challenging Circumstances I'll tell you, navigating through operational bottlenecks is no small feat, but Natura seems to be brewing its own survival recipe. They reported a net income of BRL 49 million in the third quarter of 2026, clawing back from a net loss of BRL 119 million in the previous year. That's no magic trick; it's a reflection...

Curve Dental Pushes Dental Tech with New Marketing Head

Curve Dental's Bold Move in Dental Technology Nat Harrison stepping up as Senior VP of Marketing at Curve Dental seems like a big swing for a firm already in the thick of reshaping dental practice management. Curve Dental's advancing platform boasts AI-powered, cloud-native capabilities that aim to streamline operations for dental teams stretched thin by daily demands....

Vipshop Sets 2026 AGM: Shareholders Meet on Dec 8

Blockbuster or Bust: Vipshop's Upcoming AGM Here's the scoop: Vipshop Holdings Limited, with its mammoth operations in China's off-price retail sector, is gearing up for its annual general meeting (AGM) on December 8, 2026. This is where management and stakeholders will hash out everything from strategic pivots to financial health. Forget shareholder votes this...

Nagarro's Earnings Show Stagnant Growth Amid Flat Margins

Nagarro's Financial Picture: A Glimpse Live a day in the trading pits and you'll learn to spot when a company is merely treading water. That's the vibe I'm getting from Nagarro's Q3 2026 results. They might label themselves as an AI-native leviathan, but these numbers spell out a story of struggle wrapped in fancy buzzwords. Revenue Uptick or Revenue Hiccup? For the nine...

NYSE Gains Ground with Historic Listings Transfers

You'll know it's a topsy-turvy market when hefty firms start switching their stock exchange allegiance. This year, nine noteworthy companies, with a collective market heft of nearly half a trillion dollars, kissed Nasdaq goodbye and nestled into the New York Stock Exchange (NYSE). Now, why would these big shots make the shift, you ask? Let's dive into the nitty-gritty....

Kyndryl's Sovereignty Strategy Tackles Digital Resilience

Driving Resilience Amidst Sovereignty Moves Hot off the press, Kyndryl is rolling out a beefed-up strategy to fortify operational resilience in the face of shifting digital sovereignty challenges. I’d say these guys got their fingers firmly on the geopolitical pulse, and they’re not messing around. “Maintaining critical IT operations is fundamental to business...

Xavier Ochsner Opens State-of-the-Art Medical School

A New Era for Medical Education in New Orleans If you're familiar with New Orleans, you know it's a city defined by its vibrancy, culture, and resilience. Well, the Xavier Ochsner College of Medicine is adding to that narrative with the opening of their spanking new Center for Medical Education. It's a project that promises to shake things up in the best possible way for...

EDB Bolsters AI Governance With Strategic Expertise

EDB’s Strategic Move in AI Governance EnterpriseDB (EDB) is throwing some serious weight behind their AI governance strategy by bringing in top-notch talent from CMRD. The buzz? This team didn’t just descend in a parachute—they already have their fingerprints all over the audit infrastructure of EDB’s governance solution. Now, they're officially joining EDB’s...